| abstract |
Disclosed are GLP-2 analogs comprising one or more substitutions relative to [hGly2] GLP-2 and improving biological activity in vivo and / or improving chemical stability, eg, as assessed in in vitro stability assays. do. More specifically, preferred GLP-2 analogs disclosed herein optionally include one or more additional substitutions at position 2, and positions 3, 5, 7, 10 and 11 (as mentioned in the introduction), and / or amino acids Deletion of one or more amino acids of 31 to 33 and / or one or more substitutions at positions 8, 16, 24 and / or 28 of the wild type GLP-2 sequence with addition of an N-terminal or C-terminal stabilizing peptide sequence do. Such analogs are particularly useful for the prevention or treatment of gastric and intestinal related disorders and for the improvement of side effects of chemotherapy. |